MARKET

ZIOP

ZIOP

ZIOPHARM Oncolgy
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.980
-0.220
-6.88%
After Hours: 2.980 0 0.00% 16:00 05/10 EDT
OPEN
3.180
PREV CLOSE
3.200
HIGH
3.180
LOW
2.980
VOLUME
1.53M
TURNOVER
--
52 WEEK HIGH
5.95
52 WEEK LOW
2.060
MARKET CAP
641.31M
P/E (TTM)
-7.8154
1D
5D
1M
3M
1Y
5Y
Raymond James Maintains Outperform on ZIOPHARM Oncology, Lowers Price Target to $4
Raymond James analyst David Novak maintains ZIOPHARM Oncology (NASDAQ:ZIOP) with a Outperform and lowers the price target from $5.5 to $4.
Benzinga · 3d ago
--Raymond James Adjusts Price Target on ZIOPHARM Oncology to $4 From $5.50, Maintains Outperform Rating
MT Newswires · 3d ago
Ziopharm Oncology (ZIOP) Gets a Buy Rating from Raymond James
SmarterAnalyst · 3d ago
DJ ZIOPHARM Oncology, Inc.'s Interim CEO Heidi Hagen on Q1 2021 Results -- Earnings Call Transcript >ZIOP
Dow Jones · 3d ago
8-K: ZIOPHARM ONCOLOGY INC
(EDGAR Online via COMTEX) -- ZIOPHARM ONCOLOGY INC false 0001107421 0001107421 2021-05-06 2021-05-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 4d ago
Press Release: Ziopharm Oncology Reports First -2-
Dow Jones · 4d ago
ZIOPHARM Oncology Q1 EPS $(0.10), Inline
ZIOPHARM Oncology (NASDAQ:ZIOP) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 11.11 percent decrease over losses of $(0.09) per share from the same period last year.
Benzinga · 4d ago
ZIOPHARM Oncology EPS beats by $0.01
ZIOPHARM Oncology (ZIOP): Q1 GAAP EPS of -$0.10 beats by $0.01.Cash and cash equivalents, as of March 31, 2021 were $100.1M.Press release.
Seekingalpha · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZIOP. Analyze the recent business situations of ZIOPHARM Oncolgy through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZIOP stock price target is 5.08 with a high estimate of 7.50 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 243
Institutional Holdings: 114.97M
% Owned: 53.42%
Shares Outstanding: 215.21M
TypeInstitutionsShares
Increased
40
8.78M
New
26
1.19M
Decreased
53
5.26M
Sold Out
24
679.15K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.01%
Pharmaceuticals & Medical Research
-0.44%
Key Executives
Chairman/Executive Director
James Huang
Chief Executive Officer/Director
Heidi Hagen
Chief Financial Officer
Timothy Cunningham
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Robert Hadfield
Executive Vice President/General Manager
Jill Buck
Vice President/Director of Investor Relations
David Connolly
Executive Vice President/General Manager
Eleanor De Groot
Executive Vice President/Director of Human Resources
Lynn Ferrucci
Senior Vice President - Finance/Chief Accounting Officer/Treasurer
Kevin Lafond
Other
Raffaele Baffa
Director
J. Kevin Buchi
Director
Robert Postma
Director
Jaime Vieser
Director
Holger Weis
Independent Director
Christopher Bowden
Independent Director
Mary Thistle
No Data
About ZIOP
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

Webull offers kinds of ZIOPHARM Oncology Inc. stock information, including NASDAQ:ZIOP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZIOP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZIOP stock methods without spending real money on the virtual paper trading platform.